Open an Account
search icon
3
NOTIFICATIONS
Best Algo trading app in India
Bigul

Q3FY23 Quarterly Result Announced for Indoco Remedies Ltd.

 Pharmaceutical firm Indoco Remedies announced Q3FY23 results: Q3FY23 vs Q3FY22: During the Q3FY23, revenues of Indoco Remedies grew by 17.8% at Rs 410.6 crore, as against Rs 348.6 crore, in the same quarter last year. EBIDTA to net sales for the quarter is 15.0% at Rs 61.7 crore, compared to 21.1% at Rs 73.4 crore, in the same quarter last year. EBIDTA to net sales without the impact of other operating income stands at 17.9 %. For the quarter, the profit after tax is Rs 27.9 crore. 9MFY23 vs 9MFY22: The revenues grew by 9.8% at Rs 1,210.1 crore, as against Rs 1,102.4 crore, in the same period last year. EBIDTA to net sales for the period is 18.2% at Rs 220.7 crore, compared to 22.4% at Rs 246.5 crore, in the same period last year. During the period, the profit after tax is Rs 116 crore. Commenting on the third quarter FY23 results, Aditi Panandikar, Managing Director, Indoco Remedies Ltd. said, “A good performance in Domestic business and an excellent growth in Export business has allowed us to post good results this quarter”. Result PDF
24-01-2023
Bigul

INDOCO REMEDIES LTD. - 532612 - Financial Results For The Quarter Ended 31/12/2022

 Pursuant to the Regulation 30 read with Schedule III and 33 of the SEBI (Listing Obligations and Disclosure Requirements), Regulations, 2015 ("Listing Regulations"), we hereby inform you that the Board of Directors of the Company at its Meeting held today i.e. 24% January, 2023 has inter-alia considered and approved the Unaudited Standalone and Consolidated Financial Results for the quarter and nine months ended 31st December, 2022 along with the Limited Review Report issued by the Statutory Auditor of the Company.
24-01-2023
Bigul

INDOCO REMEDIES LTD. - 532612 - Board Meeting Outcome for Outcome Of Board Meeting Held On 24'' January, 2023

 Pursuant to the Regulation 30 read with Schedule III and 33 of the SEBI (Listing Obligations and Disclosure Requirements), Regulations, 2015 ("Listing Regulations"), we hereby inform you that the Board of Directors of the Company at its Meeting held today i.e. 24% January, 2023 has inter-alia considered and approved the Unaudited Standalone and Consolidated Financial Results for the quarter and nine months ended 31st December, 2022 along with the Limited Review Report issued by the Statutory Auditor of the Company.
24-01-2023

Indoco Remedies shares gain even as USFDA inspection ends with 9 observations

 Indoco believes that this will not have an impact on the supplies and the existing revenues from this facility
23-01-2023
Bigul

INDOCO REMEDIES LTD. - 532612 - USFDA Inspection At Indoco Remedies Limited'S Solid Oral Formulation Facility (Plant 1) At Goa.

 We would like to inform you that the United States Food and Drug Administration (USFDA) has conducted GMP inspection of the Solid Oral Formulation Facility (Plant 1) at Goa. The inspection was conducted from 16th January, 2023 to 20th January 2023
23-01-2023
Bigul

INDOCO REMEDIES LTD. - 532612 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation

 Intimation of Earnings Conference Call on unaudited financial results for quarter and nine months ended 31st December 2022 is scheduled to be held on Tuesday, 24th January, 2023 at 03:30 P.M. IST.
17-01-2023

Indoco Remedies Q3 PAT seen up 46.1% YoY to Rs 482 cr: Nirmal Bang

 Net Sales are expected to increase by 18.3 percent Y-o-Y (down 2.2 percent Q-o-Q) to Rs 4,236 crore, according to Nirmal Bang.
17-01-2023
Bigul

INDOCO REMEDIES LTD. - 532612 - Board Meeting Intimation for Standalone And Consolidated Unaudited Financial Results Of The Company For The Quarter And Nine Months Ended 31St December, 2022.

 INDOCO REMEDIES LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 24/01/2023 ,inter alia, to consider and approve The standalone and consolidated unaudited financial results of the Company for the quarter and nine months ended 31st December, 2022.
11-01-2023
Bigul

INDOCO REMEDIES LTD. - 532612 - Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018

 Attached the certificate issued by Link Intime India Private Limited, Registrar and Transfer Agent of the Company, confirming compliance under Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018 for the quarter ended 31st December, 2022
10-01-2023
Bigul

INDOCO REMEDIES LTD. - 532612 - Closure of Trading Window

 Pursuant to the provisions of SEBI (Prohibition of Insider Trading) Regulations, 2015 and Company's code of conduct for regulating, monitoring and reporting of trading by insiders, this is to inform you that the Trading Window for trading/dealing in Equity Shares of the Company will remain closed from 01st January, 2023 until 48 hours after declaration of standalone and consolidated financial results of the Company for the quarter ending 31st December, 2022. During the closure of trading window, all designated persons of the Company (including their immediate relatives) have been advised not to deal in Equity Shares of the Company.
30-12-2022
Next Page
Close

Let's Open Free Demat Account